title: [Risk medications in case of glucose-6-phosphate dehydrogenase deficiency].
abstract: The best known morbid effect of glucosephosphate dehydrogenase (G-6PD) deficiency is hemolysis induced by oxidative drugs. When prescribing drugs for G-6PD deficient subjects, two points should be kept in mind: different genetic variants of G-6PD deficiency entail different susceptibility to the hemolytic risk from drugs; thus a drug found to be safe in some G-6PD deficient subjects may not be equally safe in others; the risk and severity of hemolysis is almost always dose-related. The purpose of this paper is to underline the main drugs that cannot be safely administrated to G-6PD deficient subjects. They can be separated in drugs that must be avoided by G-6PD deficient subjects (such as sulphonamides, quinolones, nitrofurantoin), and drugs that do not systematically precipitate hemolysis but must nevertheless be prescribed with caution.
authors.affiliation: Service de pharmacologie, CHRU de Tours, 2, bd Tonnellé, 37044 Tours, France.
authors.forename: L
authors.initials: L
authors.lastname: Bensouda
authors.forename: C
authors.initials: C
authors.lastname: Jarry
authors.forename: A P
authors.initials: AP
authors.lastname: Jonville-Béra
authors.forename: E
authors.initials: E
authors.lastname: Autret-Leca
mesh_terms: D002648:Child; D064420:Drug-Related Side Effects and Adverse Reactions; D005953:Glycogen Storage Disease Type I / Q000503:physiopathology*; D006801:Humans; D012307:Risk Factors
vernacular_title: Médicaments à risque en cas de déficit en glucose-6-phosphate deshydrogénase (G-6PD).